Recombinant Human DSE Protein，His

DSE (Dipeptidyl Peptidase-4, or DPP-4) is a serine protease that has garnered significant attention in recent years due to its critical role in glucose metabolism and immune regulation. Initially identified for its involvement in the inactivation of incretin hormones, such as GLP-1, which are essential for insulin secretion, DSE has emerged as a pivotal target for therapeutic intervention in diabetes management. The increasing prevalence of type 2 diabetes has prompted extensive research into DSE and its inhibitors, leading to the development of DPP-4 inhibitors as a novel class of anti-diabetic medications. These inhibitors not only improve glycemic control but also exhibit potential cardiovascular and renal benefits. Furthermore, recent studies have expanded our understanding of DSE's functions beyond glucose homeostasis, revealing its implications in inflammatory responses and cancer biology. The ongoing exploration of DSE's structural biology, including its enzyme kinetics and interaction with various substrates, is crucial for designing more effective inhibitors and understanding its broader physiological roles. This research holds promise for innovative therapeutic strategies aimed at addressing not just diabetes, but also associated metabolic disorders, making DSE a focal point in contemporary biomedical research.